Loading
SGK1 (Serine/threonine-protein kinase Sgk1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Non-Hodgkin lymphoma, Renal cell carcinoma and 2 more.
Serine/threonine-protein kinase which is involved in the regulation of a wide variety of ion channels, membrane transporters, cellular enzymes, transcription factors, neuronal excitability, cell growth, proliferation, survival, migration and apoptosis. Plays an important role in cellular stress response. Contributes to regulation of renal Na(+) retention, renal K(+) elimination, salt appetite, gastric acid secretion, intestinal Na(+)/H(+) exchange and nutrient transport, insulin-dependent salt sensitivity of blood pressure, salt sensitivity of peripheral glucose uptake, cardiac repolarisation and memory consolidation.
CIViC holds 4 clinical evidence items and 0 assertions across 2 variants, naming Alpelisib and SGK1-Inh. IntOGen calls it a driver in 6 cohorts (4 activating, 2 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma, Non-Hodgkin Lymphoma, Papillary Renal Cell Carcinoma.
In plain words · SGK1 (Serine/threonine-protein kinase Sgk1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Non-Hodgkin lymphoma, Renal cell carcinoma and 2 more.
SGK1 (Serine/threonine-protein kinase Sgk1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Non-Hodgkin lymphoma, Renal cell carcinoma and 2 more.
Serine/threonine-protein kinase which is involved in the regulation of a wide variety of ion channels, membrane transporters, cellular enzymes, transcription factors, neuronal excitability, cell growth, proliferation, survival, migration and apoptosis.
No product in this corpus aims at SGK1 yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA SGK1: RNA tissue enhanced (parathyroid gland 946 nTPM); blood lineage group enriched (granulocytes 170 nTPM, monocytes 44 nTPM); high antibody staining in 16 normal tissues; highest cancer staining pancreatic cancer (3 of 11 high). Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Breast cancer (all types), Lymphoma, Renal cell carcinoma); Open Targets associates it with 1 specific cancer type at or above 0.5 (diffuse large B-cell lymphoma). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt O00141; CIViC gene SGK1; IntOGen SGK1; Human Protein Atlas SGK1 tissue; Open Targets ENSG00000118515 associations
First described 1997. Earliest sequence paper UniProt cites for the protein: Waldegger et al, Proc. Natl. Acad. Sci. U.S.A, 1997, "Cloning and characterization of a putative human serine/threonine protein kinase transcriptionally modified during anisotonic and isotonic alterations of cell volume". Source.
Sources: HGNC HGNC:10810 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O00141 (protein name, function text, keywords and locations (REST API)); CIViC gene SGK1 (4 evidence items, 0 assertions, 2 variants; diseases: Breast Cancer, Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000118515 (per-cancer scores at or above 0.5: diffuse large B-cell lymphoma 0.53, non-Hodgkin lymphoma 0.55 (GraphQL API, CC0)); IntOGen SGK1 (driver in 6 cohorts (Act 4, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Serine/threonine-protein kinase which is involved in the regulation of a wide variety of ion channels, membrane transporters, cellular enzymes, transcription factors, neuronal excitability, cell growth, proliferation, survival, migration and apoptosis. Plays an important role in cellular stress response. Contributes to regulation of renal Na(+) retention, renal K(+) elimination, salt appetite, gastric acid secretion, intestinal Na(+)/H(+) exchange and nutrient transport, insulin-dependent salt sensitivity of blood pressure, salt sensitivity of peripheral glucose uptake, cardiac repolarisation and memory consolidation. Up-regulates Na(+) channels: SCNN1A/ENAC, SCN5A and ASIC1/ACCN2, K(+) channels: KCNJ1/ROMK1, KCNA1-5, KCNQ1-5 and KCNE1, epithelial Ca(2+) channels: TRPV5 and TRPV6, chloride channels: BSND, CLCN2 and CFTR, glutamate transporters: SLC1A3/EAAT1, SLC1A2 /EAAT2, SLC1A1/EAAT3, SLC1A6/EAAT4 and SLC1A7/EAAT5, amino acid transporters: SLC1A5/ASCT2, SLC38A1/SN1 and SLC6A19, creatine transporter: SLC6A8, Na(+)/dicarboxylate cotransporter: SLC13A2/NADC1, Na(+)-dependent phosphate cotransporter: SLC34A2/NAPI-2B, glutamate receptor: GRIK2/GLUR6. Up-regulates carriers: SLC9A3/NHE3, SLC12A1/NKCC2, SLC12A3/NCC, SLC5A3/SMIT, SLC2A1/GLUT1, SLC5A1/SGLT1 and SLC15A2/PEPT2. Regulates enzymes: GSK3A/B, PMM2 and Na(+)/K(+) ATPase, and transcription factors: CTNNB1 and nuclear factor NF-kappa-B. Location: Cytoplasm; Nucleus; Endoplasmic reticulum membrane; Cell membrane (UniProt). Locus 6q23.2 (HGNC).
RNA: tissue enhanced (parathyroid gland 946 nTPM), detected in all normal tissues. Blood: group enriched (granulocytes 170 nTPM, monocytes 44 nTPM).
Medium: Bronchus, Caudate, Cervix, Duodenum, Esophagus, Gallbladder, Heart muscle, Kidney.
Medium only: breast cancer, carcinoid, colorectal cancer, endometrial cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"SGK1" OR ABSTRACT:"SGK1" OR TITLE:"serum/glucocorticoid regulated kinase 1" OR ABSTRACT:"serum/glucocorticoid regulated kinase 1" OR TITLE:"Serine/threonine-protein kinase Sgk1" OR ABSTRACT:"Serine/threonine-protein kinase Sgk1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SGK1, not a curated reading list.
Shares Papillary renal cell carcinoma, Renal cell carcinoma, CIViC, IntOGen.
Shares Papillary renal cell carcinoma, Renal cell carcinoma, CIViC, IntOGen.
Shares Papillary renal cell carcinoma, Renal cell carcinoma, CIViC, IntOGen.
Shares Papillary renal cell carcinoma, Renal cell carcinoma, IntOGen, Non-Hodgkin lymphoma (all types).
Shares Papillary renal cell carcinoma, Renal cell carcinoma, IntOGen, Non-Hodgkin lymphoma (all types).
Shares Papillary renal cell carcinoma, Renal cell carcinoma, IntOGen.
Shares Papillary renal cell carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.
Shares Papillary renal cell carcinoma, CIViC.